Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Support

EnCode-ID project on Intellectual Disabilities receives patronage support from Mutuelles AXA

Published on: 30/11/2023 Reading time: 1 min
Un visage constitué de feuille

An Intellectual Development Disorder (IDD) is a cognitive skills development disorder beginning in early childhood. Despite advances in genetics, in around 50% of cases the cause of this neurodevelopmental disorder is still not identified. The ENCode-ID project, led by Dr. Laïla el-Khattabi within Professor. Bassem Hassan’s team, and in collaboration with the AP-HP/Sorbonne University (Armand Trousseau and Pitié-Salpêtrière hospitals) clinical and biological genetics teams, as well as Lille and Rennes teaching hospitals, has received public health sponsorship support from Mutuelles AXA, as part of the second call for projects launched in February 2023.The aim of ENCode-ID is to identify new genetic causes, severity biomarkers, as well as new therapeutic pathways.

Delayed neurodevelopment can manifest itself in many different ways at an early age, including delayed language development, toilet training, delays in learning to read, etc. When neurodevelopmental milestones are not met at the same age as other children, it is possible that a child may have an Intellectual Development Disorder (IDD). This disorder, which varies in its severity, affects between 1% and 2% of the population. The impact on the child and their family make this a major public health issue.

Genetic diagnosis crucial to treating intellectual developmental disorders

The genetic factors responsible for IDDs are manifold and heterogeneous, making them difficult to

diagnose.Significant technological progress in recent years has substantially increased diagnostic yield, up from 5% a decade ago to 50% today. Although this increase is remarkable, it is still not enough – half of all patients affected by an IDD are still undiagnosed. However, several studies emphasize the positive impact of diagnosis on care, acceptance of the pathology, removing parents’ guilt, and avoiding misdiagnosis.

Genetic diagnosis will therefore be one of the major challenges for intellectual development disorders in the coming years.

Exploring the non-coding genome to improve diagnosis of intellectual development disorders

The ENCode-ID translational medical research project conducted at Paris Brain Instituteby Dr. Laïla El-Khattabi aims to improve IDDs diagnosis rates by exploring the role of genetic variants in non-coding genome sequences. This work should have an immediate impact on patients and their families, particularly for their care and genetic counseling.In addition, the work will generate a considerable amount of data that can be used by the teams at  Paris Brain Institute and by the international community.

Dr Laïla El-Khattabi
Dr Laïla El-Khattabi

ENCode-ID is the first study to propose a comprehensive approach to large-scale functional studies of mutations in non-coding regulatory genomic regions. The project is not just innovative in its approach, but also innovative in the techniques it deploys: multiplex genome editing, use of brain organoids as a model, single cell analysis techniques and innovative bioinformatics tools.

In addition, this is currently the only study to propose in silico exploration of therapeutic pathways for an IDD in a model that closely mimics early brain development in humans, using an algorithm for restoring altered developmental trajectories. This is all made possible through the advanced skills of the lead team, the collaboration with leading clinical teams specializing in this type of disorder, and Paris Brain Institute’s unique expertise and core technological and bioinformatics facilities.

The innovative holistic approach of the encode-id project, supported by Mutuelles Axa's mutual

The ENCode-ID project has successfully secured the support of Mutuelles AXA and will receive healthcare patronage funding over two years, as part of its program dedicated to supporting innovative research initiatives in France.

The healthcare patronage program launched by Mutuelles AXA  in early 2022 is a new commitment that complements its traditional patronage focus areas in support of social, environmental and national heritage causes.

Paris Brain Institute and its teams wish to thank Mutuelles AXA for its continued support.

Our news on the subject

Visuel Voeux 2025
2025: An ambitious dynamic led by Prof. Stéphanie DEBETTE, the new Executive Director of the Institute since January 1, 2025
Professor Gérard SAILLANT, President of Paris Brain Institute, extends his warmest wishes to all those who, by faithfully supporting the research carried out at the institute, enable us to make a tangible difference in our fight against brain...
01.08.2025 Institutional
À la recherche de marqueurs d’imagerie dans la démence frontotemporale
Searching for Imaging Markers in Frontotemporal Dementia
Could exploring the relationships between different brain networks help us understand frontotemporal dementia (FTD)? This neurodegenerative disease, which progresses at varying rates, is often diagnosed late—when clinical signs are already severe. At...
01.07.2025 Research, science & health
Remise du chèque Amour, Amour, Amour
Amour, Amour, Amour: An Unwavering Support for Brain Tumor Research
On November 23rd, the association Amour, Amour, Amour once again demonstrated its commitment to brain tumor research. During the association's annual event, its members presented a cheque for €100,000 to the Paris Brain Institute, marking yet another...
11.28.2024 Support
Un pilote de course
A Unique Alliance with 2025 Le Mans Classic
For the upcoming edition of Le Mans Classic, an unprecedented alliance has been formed between the Automobile Club de l’Ouest (ACO) and Paris Brain Institute. This collaboration will allow spectators to make a €2 donation when purchasing their...
11.26.2024 Support
Monocyte – un globule blanc qui se différencie en macrophage. Crédit : Université d’Edinbourg.
Discovery of a Macrophage Anomaly in Multiple Sclerosis
Certain patients with multiple sclerosis (MS) can partially regenerate myelin—the protective sheath that surrounds nerve fibers—which is damaged during the evolution of the disease. In studying how immune cells influence this remyelination...
12.19.2024 Research, science & health
Les participants du Dîner annuel de Paris Brain Institute America
Annual Dinner of Paris Brain Institute America at the French Consulate in New York – A Resounding Success for Neuroscience Research
On October 8, 2024, the French Consulate in New York hosted the annual dinner of Paris Brain Institute America (PBIA), gathering prominent philanthropists and influential figures from the scientific community for an evening dedicated to transatlantic...
10.15.2024 Support
See all our news